文献速递骨质疏松与代谢性骨病

阿巴洛肽与罗莫索单抗的真实世界比较:骨密度与三维髋部结构效应

Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure.
PubMed 文献 · Osteoporos Int · 2026-09-28

12个月内两组腰椎、全髋和股骨颈骨密度均显著增加,组间无显著差异;探索性三维髋部结构参数亦改善,组间无显著差异。

要点

  • 阿巴洛肽与罗莫索单抗治疗12个月均显著提高腰椎、全髋和股骨颈骨密度。
  • 两组骨密度增幅及达到T值>-2.5的比例均无显著组间差异。
  • 探索性三维髋部骨小梁与骨皮质结构参数改善,组间无显著差异。

核心结论

  • 在高骨折风险初治绝经后骨质疏松女性中,阿巴洛肽与罗莫索单抗治疗前12个月均显著改善骨密度和股骨近端结构参数,组间无显著差异。

主要发现

  • 12个月时两组腰椎、全髋和股骨颈骨密度均较基线显著增加(均P < 0.001),组间无显著差异。
  • 两组达到T值>-2.5的患者比例随时间增加,组间无显著差异。
  • 探索性3D-Shaper分析显示12个月内多个骨小梁和骨皮质结构参数改善,所有参数组间均无显著差异。

关键数值与推荐

  • 主要终点为12个月内腰椎、全髋和股骨颈骨密度百分比变化。
  • 次要及探索性终点包括T值阈值达标情况、骨转换标志物和基于DXA的3D-Shaper结构参数。
  • 纵向变化采用重复测量混合模型评估。

临床怎么用

  • 对于高骨折风险初治绝经后骨质疏松女性,阿巴洛肽与罗莫索单抗均可作为改善骨密度和髋部结构的选项。
  • 短期12个月内两药在骨密度和三维髋部结构方面未显示显著差异,选择时可综合考虑其他因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In a real-world study of postmenopausal women with high-risk osteoporosis, abaloparatide and romosozumab significantly improved bone mineral density and threedimensional hip structural parameters over 12 months, with no significant between-group differences observed. PURPOSE: Direct real-world comparisons between abaloparatide and romosozumab, particularly incorporating structural assessment beyond areal bone mineral density (BMD), remain limited. METHODS: This nationwide multicenter propensity score-matched cohort study compared the effects of abaloparatide and romosozumab on BMD and three-dimensional proximal femur structural parameters in treatment-naïve postmenopausal women with osteoporosis at high fracture risk. Fifty-one matched patients were included in each group. Primary endpoints were percentage changes in lumbar spine (LS), total hip (TH), and femoral neck (FN) BMD over 12 months. Secondary and exploratory endpoints included achievement of T-score thresholds, bone turnover markers, and DXA-based 3D-Shaper structural parameters. Longitudinal changes were assessed using mixed models for repeated measures. RESULTS: Both groups demonstrated significant increases in BMD at all skeletal sites at 12 months (all P < 0.001), with no significant between-group differences. The proportion of patients achieving a T-score > -2.5 increased over time in both groups without significant between-group differences. Exploratory 3D-Shaper analyses demonstrated improvements in several trabecular and cortical structural parameters over 12 months, with no significant between-group differences in any parameter. CONCLUSION: In this real-world propensity score-matched cohort, abaloparatide and romosozumab significantly improved BMD and proximal femur structural parameters over the first 12 months of treatment. No significant between-group differences were observed during this period.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kobayakawa T, Takenaka H, Kobayashi T, et al. Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure. Osteoporos Int. 2026. PMID: 42803810. doi:10.1007/s00198-026-08241-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。